PR-15 is under clinical development by AdvanceCor and currently in Phase II for Acute Coronary Syndrome. According to GlobalData, Phase II drugs for Acute Coronary Syndrome have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PR-15’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PR-15 overview

PR-15 (revacept, GPVI-Fc) is under development for the treatment of symptomatic carotid stenosis, acute coronary syndrome, transient-ischemic attacks, Amaurosis fugax or stroke and peripheral arterial disease (PAD). It is administered through intravenous route. The drug candidate targets platelet glycoprotein VI. It is a fusion protein consisting of the Fc part of human IgG1 GPVI (glycoprotein VI). The drug candidate was also under development for the treatment of atherosclerosis.

AdvanceCor overview

advanceCor (AdvanceCor) that engaged in developing innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. The company is headquartered in Martinsried, Planegg, Germany.

For a complete picture of PR-15’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.